Catalent, Inc.
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067
info@portnoylaw.com
According to the complaint, the Defendants are accused of making false and misleading statements or failing to disclose crucial information during the class period. The alleged misconduct includes: a) Catalent overstating its revenue and earnings by recognizing revenue before it was due under GAAP; b) Catalent having significant weaknesses in its internal control over financial reporting with respect to revenue recognition; c) Catalent misleadingly portraying the demand for its products while knowingly selling more products to its direct customers than could be sold to healthcare providers and end consumers; d) Catalent breaching regulatory rules at key production facilities in order to produce excess inventory that was used to inflate the company’s financial results by prematurely recognizing revenue or providing it to direct customers; and e) as a result of the above, the defendants did not have a sound basis for their optimistic statements about the company’s financial performance, outlook, and regulatory compliance during the class period.
